Lynch syndrome (LS), also known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC), is an autosomal dominant cancer syndrome which causes about 2–3% of cases of colorectal carcinoma. The development of LS is due to the genetic and epigenetic inactivation of genes involved in the DNA mismatch repair (MMR) system, causing an epiphenomenon known as microsatellite instability (MSI). Despite the fact that the genetics of the vast majority of MSI-positive (MSI+) cancers can be explained, the etiology of this specific subset is still poorly understood. As a possible new mechanism, it has been recently demonstrated that the overexpression of certain microRNAs (miRNAs, miRs), such as miR-155, miR-21, miR-137, can induce MSI or modulate the expression of the genes involved in LS pathogenesis. MiRNAs are small RNA molecules that regulate gene expression at the post-transcriptional level by playing a critical role in the modulation of key oncogenic pathways. Increasing evidence of the link between MSI and miRNAs in LS prompted a deeper investigation into the miRNome involved in these diseases. In this regard, in this study, we discuss the emerging role of miRNAs as crucial players in the onset and progression of LS as well as their potential use as disease biomarkers and therapeutic targets in the current view of precision medicine.
Background: Differentiating adrenal adenomas from non-adenomatous lesions remains a critical challenge in the management of adrenal incidentalomas. Conventional unenhanced CT relies on attenuation thresholds of 10 HU and 20 HU, which present trade-offs between sensitivity and specificity. Objectives: To evaluate the diagnostic performance of unenhanced Spectral CT using the attenuation difference between 40 keV and 140 keV virtual monoenergetic images for differentiating adrenal adenomas from non-adenomatous lesions. Methods: In this retrospective single-center study, 60 patients with adrenal lesions who underwent unenhanced dual-energy CT were included. Mean attenuation values were measured on conventional images and on virtual monoenergetic images at 40 keV and 140 keV. The spectral attenuation difference (Δ40–140 keV) was calculated. ROC analysis was performed to determine the optimal threshold and diagnostic performance. Additional analyses included DeLong comparison of correlated ROC curves and bootstrap resampling to estimate 95% confidence intervals for the area under the curve. Results: Forty-nine lesions were adenomas and eleven were non-adenomatous. The optimal threshold for Δ40–140 keV was −17 HU. When evaluated as a continuous variable, Δ40–140 keV yielded an area under the curve of 0.940 (95% confidence interval: 0.851–1.000), compared with 0.939 (95% confidence interval: 0.870–0.992) for conventional unenhanced attenuation. DeLong comparison showed no statistically significant difference between the two curves (p = 0.980). Diagnostic performance was as follows: HU ≤ 10 (AUC 0.816, diagnostic accuracy 0.70), HU ≤ 20 (AUC 0.883, diagnostic accuracy 0.87), and Δ40–140 keV ≤ −17 HU (AUC 0.940, diagnostic accuracy 0.90). The spectral attenuation difference demonstrated the highest overall diagnostic accuracy. Conclusions: Unenhanced Spectral CT using Δ40–140 keV improves discrimination between adrenal adenomas and non-adenomatous lesions compared with conventional attenuation thresholds. This technique may reduce indeterminate findings and limit the need for additional imaging.
Background: Differentiating adrenal adenomas from non-adenomatous lesions remains a critical challenge in the management of adrenal incidentalomas. Conventional unenhanced CT relies on attenuation thresholds of 10 HU and 20 HU, which present trade-offs between sensitivity and specificity. Objectives: To evaluate the diagnostic performance of unenhanced Spectral CT using the attenuation difference between 40 keV and 140 keV virtual monoenergetic images for differentiating adrenal adenomas from non-adenomatous lesions. Methods: In this retrospective single-center study, 60 patients with adrenal lesions who underwent unenhanced dual-energy CT were included. Mean attenuation values were measured on conventional images and on virtual monoenergetic images at 40 keV and 140 keV. The spectral attenuation difference (Δ40–140 keV) was calculated. ROC analysis was performed to determine optimal thresholds and diagnostic performance. Results: Forty-nine lesions were adenomas and eleven were non-adenomatous. The optimal threshold for Δ40–140 keV was −17 HU. Diagnostic performance was as follows: HU ≤10 (AUC 0.816, diagnostic accuracy 0.70), HU ≤20 (AUC 0.883, diagnostic accuracy 0.87), and Δ40–140 keV ≤ −17 HU (AUC 0.940, diagnostic accuracy 0.90). The spectral attenuation difference demonstrated the highest overall diagnostic accuracy. Conclusions: Unenhanced Spectral CT using Δ40–140 keV improves discrimination between adrenal adenomas and non-adenomatous lesions compared with conventional attenuation thresholds. This technique may reduce indeterminate findings and limit the need for additional imaging.